Efficacy and Safety of an Oral Growth Hormone Drug in the Treatment of Fibromyalgia
Status:
Completed
Trial end date:
2008-04-01
Target enrollment:
Participant gender:
Summary
This is a 24-week, randomized, double-blind, placebo-controlled, trial to evaluate the
safety, tolerability and efficacy of an orally administered growth hormone stimulating drug,
(code named MK-0677) in the treatment of female subjects with primary fibromyalgia. The basis
for this study is the observation that many fibromyalgia patients are growth hormone
deficient; an earlier study of injectable growth hormone had shown benefit in this population
of fibromyalgia patients.